Digital RESI June Welcomes BioHealth Capital Region as a Gold Sponsor Next Phase Newsletter

The action item today is keeping up your business momentum in these challenging days. LSN has seen a distinct uptick in global regional-based tech hubs taking advantage of Digital RESI to expand into the new digital paradigm of global partnering conferences. The main strategy is to get the early stage companies back in the mix and secondly, to showcase the technology assets that are teeming in these dynamic regional hubs. The BioHealth Capital Region is a perfect example of deciding to take advantage of RESI and to expand their global reach.



GAITHERSBURG, Md. — The U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) is pleased to announce the appointment of Mojdeh Bahar as associate director for innovation and industry services (ADIIS). In this capacity, she will report to Under Secretary of Commerce for Standards and Technology and NIST Director Walter G. Copan and serve as a member of the NIST senior leadership team. 

Image: Mojdeh Bahar will serve as NIST's second associate director for innovation and industry services. - The Daily Record

Johns Hopkins Launches Hub for Immunology and Engineering Research

It seems like there will never be enough “thank you’s” for the incredible doctors, nurses technicians and support staff members who are working around the clock to help patients with this dangerous disease. It is their dedication, determination and spirit that allow Johns Hopkins to deliver the promise of medicine.



Six Key Takeaways for Entrepreneurs and Startups on Fundraising and How Investors View the Post-Coronavirus Landscape  Over 200 entrepreneurs, startup company executives and those with aspirations of starting a BioHealth company turned in for a live, virtual panel discussion to learn about how COVID-19 is impacting access to the capital every company needs to succeed. 

Panelists included notable investors such as Andrea Alms, Co-Fund Manager at BioHealth Capital; Adam Dakin, Managing Director at DreamIT HealthTech; Matthew Miessau, Associate at Epidarex Capital; and Adair Newhall, Principal at Greenspring Associates. 



Biological innovations could help us meet some of the great global challenges of our time. This new infographic from McKinsey Global Institute shows the potential impact of the #BioRevolution.



The Children’s National Research Institute recently released its 2019-2020 academic annual report, titled 150 Years Stronger Through Discovery and Care to mark the hospital’s 150th birthday. Not only does the annual report give an overview of the institute’s research and education efforts, but it also gives a peek in to how the institute has mobilized to address the coronavirus pandemic.

“Our inaugural research program in 1947 began with a budget of less than $10,000 for the study of polio — a pressing health problem for Washington’s children at the time and a pandemic that many of us remember from our own childhoods,” says Vittorio Gallo, Ph.D., chief research officer at Children’s National Hospital and scientific director at Children’s National Research Institute. “Today, our research portfolio has grown to more than $75 million, and our 314 research faculty and their staff are dedicated to finding answers to many of the health challenges in childhood.”

Image: Children’s National Research Institute directors Vittorio Gallo, Ph.D., and Mark Batshaw, M.D.

Af2f28d8 75ec 458b a7ee e454b4449d37 pdf

Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® REIT, is the first and longest-tenured owner, operator, and developer uniquely focused on collaborative life science, technology , and agtech campuses in AAA innovation cluster locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in life science, technology, and agtech campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success.


Students across the University System of Maryland are graduating. But there are no auditoriums and arenas packed with people, cheering and taking photos as their children, grandchildren, spouses, parents and friends cross the stage. There is no stage. But there are virtual ceremonies online, produced with as much fanfare as our universities can create.

This isn’t the way graduates wanted to celebrate their enormous accomplishment. It isn’t how our universities wanted to celebrate their graduates. But COVID-19 has subordinated what we want to do in service of what we need to do — for the safety of our students, faculty, staff and neighbors.


Remote medicine. Telehealth. Digital medicine. Virtual visits.

Whatever it might be called, Children’s National Hospital (Children’s National) has been developing and deploying innovative telemedicine protocols, technologies and approaches for nearly two decades. 

So when the pandemic hit the region full force in mid-March 2020, Children’s National was ready. 

As COVID-19 took hold, the way patients engaged with medical professionals shifted nearly overnight. What was once seen as the future of medical treatment had suddenly, and perhaps irrevocably, been transformed into the standard of care for children and adults unable or unwilling to physically visit their healthcare provider because of the pandemic.


I Corps

The National Science Foundation’s Innovation Corps (I-Corps™) program uses experiential education to help researchers gain valuable insight into entrepreneurship, starting a business or industry requirements and challenges.

I-Corps enables the transformation of invention to impact. The curriculum integrates scientific inquiry and industrial discovery in an inclusive, data-driven culture driven by rigor, relevance, and evidence. Through I-Corps training, researchers can reduce the time to translate a promising idea from the laboratory to the marketplace.


5 Questions with Byung Ha Lee Director R D at NeoImmuneTech Inc BioBuzz

“5 Questions With……” is a new BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. We’re happy to have NeoImmuneTech’s Byung Ha Lee as our 2nd guest.

Byung Ha Lee is the Director, R&D at NeoImmuneTech, Inc. With degrees from Korea University, and his Ph.D. in Medical Sciences-immunology and microbiology from the University of Florida College of Medicine. He has extensive industry experience over 15 years in translational research, business development, field KOL interaction, leading strategic and research planning of drug development. Byung Ha finished his postdoctoral training at the NIAID at NIH.


AstraZeneca Logo

BARDA is dispatching another billion dollars-plus for the war on Covid-19, lining up 300 million doses for the US that could start arriving as soon as October.

Allied with researchers at Oxford University on one of the leading vaccines now in development for Covid-19, AstraZeneca reported that it has secured more than $1 billion from BARDA for the development, production and delivery of the vaccine, starting in the fall. The injection dwarfs the additional £84 million ($102 million) in funding for 30 million doses (up to 100 million doses) from the United Kingdom, which envisions inoculating at least half its population by September.



Baltimore, Md. (May 20, 2020) – University System of Maryland (USM) Chancellor Jay A. Perman and USM Board of Regents Chair Linda Gooden today announced that Dr. Stewart Edelstein, executive director of the Universities at Shady Grove (USG) and USM associate vice chancellor for academic affairs, has agreed to serve in his current position at USG through September 30, 2020, while the search for a new executive director continues. Dr. Edelstein’s existing contract would otherwise have expired on June 30.



Becker's Healthcare is pleased to release the 2020 edition of its list of "100 great hospitals in America."

The hospitals included on this list have been recognized nationally for excellence in clinical care, patient outcomes, and staff and physician satisfaction. These institutions are industry leaders that have achieved advanced accreditation and certification in several specialties. The list also includes industry innovators that have sparked trends in healthcare technology, hospital management and patient satisfaction.



The most promising Covid-19 treatments and vaccines being explored right now were made possible by a little-known law that encourages licensing agreements between private pharmaceutical companies and government-funded researchers.

Treatments such as Gilead’s remdesivir, Ridgeback Biotherapeutics’ EIDD-2801 drug, and Moderna’s vaccine candidate were all achieved through public-private partnerships that didn’t exist before the Bayh-Dole Act in 1980.

image:  A magnified coronavirus is displayed on a desktop computer monitor during coronavirus patient sample detection tests in the virology research labs at UZ Leuven university hospital in Leuven, Belgium, on Feb. 28, 2020.

Photographer: Geert Vanden Wijngaert/Bloomberg